Long-Term Efficacy of Mepolizumab at 3 Years in Patients with Severe Asthma: Comparison with Clinical Trials and Super Responders

Long-Term Efficacy of Mepolizumab at 3 Years in Patients with Severe Asthma: Comparison with Clinical Trials and Super Responders

The efficacy mepolizumab in severe asthmatic patients is proven in the literature. Primarily to study the effect of mepolizumab on exacerbations, steroid dependence, and the continuation of efficacy in the long term. Secondarily to evaluate the effect of the drug on nasal polyps. Analyzing data from...

Full description

Bibliographic Details
Main Authors: Diego Bagnasco, Stefania Nicola, Elisa Testino, Luisa Brussino, Laura Pini, Marco Caminati, Federica Piccardo, Rikki Frank Canevari, Laura Melissari, Alessandro Ioppi, Luca Guastini, Carlo Lombardi, Manlio Milanese, Francesca Losa, Michela Robbiano, Laura De Ferrari, Anna Maria Riccio, Giuseppe Guida, Marco Bonavia, Donatella Fini, Francesco Balbi, Cristiano Caruso, Pierluigi Paggiaro, Francesco Blasi, Enrico Heffler, Giovanni Paoletti, Giorgio Walter Canonica, Gianenrico Senna, Giovanni Passalacqua, on behalf of SANI
Format: Article
Language:English
Published: MDPI AG 2023-08-01
Series:Biomedicines
Subjects:
severe asthma
eosinophils
mepolizumab
CRSwNP
IL-5
real life
Online Access:https://www.mdpi.com/2227-9059/11/9/2424

Similar Items

Similar Items